Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Tivozanib Eye Drops (KHK4951) in Healthy Volunteers and Wet AMD
NCT04594681Phase 1Terminated
- Sponsor
- Kyowa Kirin
- Start
- Sep 2020
- Primary completion
- Aug 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tivozanib in exudative macular degeneration (2 arms), sponsored by Kyowa Kirin. Primary endpoint: Number of participants with adverse events. Started Sep 2020; status: terminated.
02
Drugs
tivozanib
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT04594681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04594681.